NASH-FibroTest is a complete diagnostic test for the liver

Se realizează fără durere, este ușor de utilizat și nu este costisitor, oferind în același timp standarde înalte de performanță.

NASH-FibroTest™ offers an end-to-end liver diagnostic service from a single blood sample.

BioPredictive's five main diagnostic tests are included in NASH-FibroTest, for a complete assessment of the condition of the liver and the five main causes of liver disease 1 .

NASH-FibroTest = FibroTest + SteatoTest 2 + NashTest 2 + ActiTest + AshTest

Boli metabolice, steatoză

Hepatic steatosis, which is assessed by the SteatoTest 2, is a build-up of fat in the liver, which frequently causes elevated levels of Gamma-GT and transaminases.

Non-alcoholic steatohepatitis (NASH) is an inflammatory disease of the liver which is caused by metabolic conditions including excess weight, arterial hypertension (high blood pressure) and abnormal levels of triglycerides or cholesterol. The NashTest 2 evaluates the level of necroinflammatory activity caused by the metabolic condition.

Steatohepatita alcoolică (ASH) este o boală inflamatorie a ficatului cauzată de consumul excesiv de alcool. Testul AshTest evaluează nivelul acestei activități necroinflamatorii cauzate de alcool.

Fibroză și activitate

FibroTest estimates the level of hepatic fibrosis and cirrhosis, while ActiTest estimates the level of activity.

Fibroza și activitatea necroinflamatorie sunt principalele două cauze ale hepatopatiei.

Fibroza este o afecțiune medicală cauzată de reacția ficatului bolnav. Fibroza hepatică este comparată de obicei cu o formă de țesut de cicatrizare care avansează pe suprafața ficatului. Cea mai gravă formă de fibroză este cunoscută drept ciroză.

Activitatea se referă la nivelul de inflamație a ficatului cauzată de boală. Adesea este comparată cu o arsură.

Recommendations and validations

FibroTest

FibroTest este recomandat de WHO - Asociația Mondială a Sănătății 2 , Asociația Americană pentru Studiul Hepatopatiilor (AASLD) 3 , Asociația Europeană pentru Studiul Ficatului (EASL) 4 și Asociația Asia-Pacific pentru Studiul Ficatului (APASL) 5 pentru testarea fibrozei hepatice la pacienții cu hepatită C cronică, cu sau fără co-infectări cu HIV, cât și pentru pacienții cu afecțiuni metabolice sau care consumă alcool în exces. 6 7 8

FibroTest is used to give access to non-interferon treatments for combating the hepatitis C virus and for patient monitoring 9 .

Atunci când este combinat cu ActiTest, testul FibroTest face posibilă identificarea purtătorilor asimptomatici ai virusului hepatic B, dar și a posibilelor tratamente 10 .

FibroTest este conceput special pentru ciroză și este aprobat pentru clasificarea gradului de gravitate a bolii în una din cele trei clase 11 .

FibroTest este singurul test capabil să clasifice stadiile incipiente ale fibrozei 12 .

FibroTest poate fi utilizat pentru monitorizarea longitudinală a pacienților cu hepatopatie cronică 9 13 14 .

ActiTest

Testul ActiTest este superior ALT-ului, care este biomarkerul standard pentru activitatea necroinflamatorie 15 .

ActiTest și FibroTest fac posibilă identificarea purtătorilor asimptomatici de hepatită B 15 .

ActiTest și FibroTest fac posibilă identificarea posibilelor tratamente și monitorizarea progresului hepatitei virale cronice 9 .

ActiTest este un biomarker cantitativ care a fost validat la subiecții cu un risc metabolic ridicat, însoțit sau nu de obezitate severă 16 7 .

SteatoTest 2

SteatoTest 2 estimates the degree of steatosis in subjects at high metabolic risk, patients who consume excess alcohol or chronic carriers of the hepatitis B or C viruses. 17 1 18 19 11 20 7

As a quantitative biomarker for steatosis, SteatoTest 2 allows longitudinal monitoring to be performed on patients. 13 14

SteatoTest 2 is approved as a predictor of cardiovascular risk associated with steatosis 21 .

SteatoTest 2 is equivalent to SteatoTest (non-inferiority) but more convenient (no BMI, no bilirubin) 22 .

NashTest 2

NashTest 2 estimates the liver inflammation as a quantitative assessment 23 of steatohepatitis and the prediction of liver outcome 24 .

NashTest 2 is constructed using updated histological consensus on NASH definition and meets the requirements of the new SAF scoring system 25 7 .

It is a quantitative test, assessing the severity of the liver inflammation (NASH), without the need of BMI.

NashTest 2, when combined with FibroTest, has demonstrated its value in screening for NASH in patients with metabolic risk factors 26 27 28 .

AshTest

AshTest 29 este o alternativă rapidă la biopsiile hepatice transjugulare, care face așadar posibilă tratarea steatohepatitei alcoolice acute (ASH) la pacienții care suferă de hepatopatii provocate de consumul de alcool 30 18 29 19 .

10 componente, 5 scoruri

NASH-FibroTest combines ten standard biomarkers:

  • Alpha-2-macroglobulină
  • Haptoglobină
  • Apolipoproteina A1
  • Bilirubină totală
  • Gamma-GT
  • Alanine aminotransferaza (ALT)
  • Aspartate aminotransférase (AST)
  • Întreruperea consumului de glucoză
  • Colesterol
  • Trigliceride

These markers are weighted depending on the patient's age, sex.

NASH-FibroTest tests must be done on an empty stomach in any local medical test laboratory that complies with BioPredictive's technical recommendations.

There is NO NEED for patient's BMI, nor its weight or height.

Unde se poate face testul   Recomandări tehnice  

Mai multe informații

NASH-FibroTest in metabolic conditions
NASH-FibroTest for excessive alcohol intake
FibroTest-ActiTest pentru purtătorii virusului hepatic C (HCV)
FibroTest-ActiTest pentru pacienții cu virusul hepatic B (HBV)
FibroTest-ActiTest pentru pacienții infectați cu hepatita C și HIV sau cu hepatita B și HIV
Cum citim foaia de rezultat ?

You can also access all the scientific literature about NASH-FibroTest, and the latest news on non-invasive testing for the liver.

FibroTest-ActiTest

FibroTest și ActiTest sunt disponibile și separat.

Mai multe informații  

Referințe

  1. Morra R, Munteanu M, Imbert-Bismut F, Messous D, Ratziu V, Poynard T. FibroMAX: towards a new universal biomarker of liver disease? Expert Rev. Mol. Diagn. 2007;7:5. sumar articol
  2. . Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection book 2014;None:None. sumar
  3. . Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:3. sumar articol
  4. . EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol. 2015;63:1. sumar articol
  5. Shiha G, Sarin SK, Ibrahim AE, Omata M, Kumar A, Lesmana LA, Leung N, Tozun N, Hamid S, Jafri W, Maruyama H, Bedossa P, Pinzani M, Chawla Y, Esmat G, Doss W, Elzanaty T, Sakhuja P, Nasr AM, Omar A, Wai CT, Abdallah A, Salama M, Hamed A, Yousry A, Waked I, Elsahar M, Fateen A, Mogawer S, Hamdy H, Elwakil R. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int 2009;3:2. sumar articol
  6. . EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts 2016;9:2. sumar articol
  7. Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, Trauner M, Romero Gomez M, Oliveira C, Day C, Dufour JF, Bellentani S, Ngo Y, Traussnig S, Perazzo H, Deckmyn O, Bedossa P, Ratziu V, Poynard T. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Aliment. Pharmacol. Ther. 2016;44:8. sumar articol
  8. . EASL clinical practical guidelines: management of alcoholic liver disease. J. Hepatol. 2012;57:2. sumar articol
  9. Poynard T, Ngo Y, Munteanu M, Thabut D, Massard J, Moussalli J, Varaud A, Benhamou Y, Ratziu V. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Antivir. Ther. (Lond.) 2010;15:4. sumar articol
  10. Poynard T, Vergniol J, Ngo Y, Foucher J, Thibault V, Munteanu M, Merrouche W, Lebray P, Rudler M, Deckmyn O, Perazzo H, Thabut D, Ratziu V, De Lédinghen V. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®). J. Hepatol. 2014;61:5. sumar articol
  11. Poynard T, Vergniol J, Ngo Y, Foucher J, Munteanu M, Merrouche W, Colombo M, Thibault V, Schiff E, Brass CA, Albrecht JK, Rudler M, Deckmyn O, Lebray P, Thabut D, Ratziu V, De Lédinghen V. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®). J. Hepatol. 2014;60:4. sumar articol
  12. Houot M, Ngo Y, Munteanu M, Marque S, Poynard T. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment. Pharmacol. Ther. 2016;43:1. sumar articol
  13. Ratziu V, De Lédinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP, Rivière M, Spénard J. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J. Hepatol. 2011;54:5. sumar articol
  14. Lassailly G, Caiazzo R, Hollebecque A, Buob D, Leteurtre E, Arnalsteen L, Louvet A, Pigeyre M, Raverdy V, Verkindt H, Six MF, Eberle C, Patrice A, Dharancy S, Romon M, Pattou F, Mathurin P. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol 2011;23:6. sumar articol
  15. Poynard T, Munteanu M, Ngo Y, Castéra L, Halfon P, Ratziu V, Imbert-Bismut F, Thabut D, Bourliere M, Cacoub P, Messous D, De Lédinghen V. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Gastroenterol. Clin. Biol. 2010;34:6-7. sumar articol
  16. Poynard T, Lassailly G, Diaz E, Clement K, Caiazzo R, Tordjman J, Munteanu M, Perazzo H, Demol B, Callafe R, Pattou F, Charlotte F, Bedossa P, Mathurin P, Ratziu V. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS ONE 2012;7:3. sumar articol
  17. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, Capron D, Abella A, Massard J, Ngo Y, Munteanu M, Mercadier A, Manns M, Albrecht J. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005;4:None. sumar articol
  18. Supronowicz Ł, Wójtowicz E, Cylwik B, Gruszewska E, Chrostek L. [The diagnostic value of non-invasive biochemical biomarkers in alcohol abuse]. Pol. Merkur. Lekarski 2013;35:207. sumar
  19. Gudowska M, Wójtowicz E, Cylwik B, Gruszewska E, Chrostek L. The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test. Adv Clin Exp Med 2015;24:5. sumar articol
  20. Munteanu M, Houot M, Ngo Y, Poynard T. Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B. Am. J. Gastroenterol. 2014;109:8. sumar articol
  21. Perazzo H, Munteanu M, Ngo Y, Lebray P, Seurat N, Rutka F, Couteau M, Jacqueminet S, Giral P, Monneret D, Imbert-Bismut F, Ratziu V, Hartemann-Huertier A, Housset C, Poynard T. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. Aliment. Pharmacol. Ther. 2014;40:9. sumar articol
  22. sumar
  23. Poynard T, Munteanu M, Charlotte F, Perazzo H, Ngo Y, Deckmyn O, Pais R, Merrouche W, De Lédinghen V, Mathurin P, Ratziu V. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Eur J Gastroenterol Hepatol 2018;30:5. sumar articol
  24. Munteanu M, Pais R, Peta V, Deckmyn O, Moussalli J, Ngo Y, Rudler M, Lebray P, Charlotte F, Thibault V, Lucidarme O, Ngo A, Imbert-Bismut F, Housset C, Thabut D, Ratziu V, Poynard T. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Aliment. Pharmacol. Ther. 2018;48:10. sumar articol
  25. sumar
  26. Ratziu V, Giral P, Munteanu M, Messous D, Mercadier A, Bernard M, Morra R, Imbert-Bismut F, Bruckert E, Poynard T. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment. Pharmacol. Ther. 2007;25:2. sumar articol
  27. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, Goldiner I, Blendis L, Halpern Z, Oren R. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008;48:6. sumar articol
  28. Zelber-Sagi S, Salomone F, Webb M, Lotan R, Yeshua H, Halpern Z, Santo E, Oren R, Shibolet O. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. Transl Res 2015;165:3. sumar articol
  29. Rudler M, Mouri S, Charlotte F, Cluzel P, Ngo Y, Munteanu M, Lebray P, Ratziu V, Thabut D, Poynard T. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis. PLoS ONE 2015;10:8. sumar articol
  30. Thabut D, Naveau S, Charlotte F, Massard J, Ratziu V, Imbert-Bismut F, Cazals-Hatem D, Abella A, Messous D, Beuzen F, Munteanu M, Taieb J, Moreau R, Lebrec D, Poynard T. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. J. Hepatol. 2006;44:6. sumar articol
  1. Pagina principală
  2. Produsele noastre
  3. NASH-FibroTest
Despre BioPredictive

BioPredictive is an independent bio-pharmaceutical company, based in France, which designs and markets diagnostic tests for liver diseases, in particular FibroTest and NASH-FibroTest.

Contactați-ne  Twitter  FaceBook
Abonare la newsletter-ul nostru: